Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.

Cancer Pharmacogenomics

STOCCO, GABRIELE;
2011-01-01

Abstract

Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of pharmacogenomics to the clinic. This review addresses how inherited (germline) and acquired (somatic) sources of genome variability can alter the toxicity or efficacy of cancer chemotherapy.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2692209
 Avviso

Registrazione in corso di verifica.
La registrazione di questo prodotto non è ancora stata validata in ArTS.

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 25
social impact